Celebrating 10 years of the Antifibrotic Drug Development Summit
Year after year, attendees continue to return to our premier cross-fibrosis conference to stay ahead of the latest scientific and commercial developments in the field. This year is no exception, with significant industry news and investment flow, especially with United Therapeutics’ supplemental New Drug Application for nebulized Tyvaso® in IPF, bringing the field one step closer to the first inhaled antifibrotic treatment for the disease.
But don’t just take our word for it, see what our past attendees have to say:
On Event Content:
On Networking:
Fantastic meeting to exchange with experts across industry and academia to understand challenges and opportunities in antifibrotic drug discovery, with the common goal to accelerate development of new treatment options for patients in need
Senior Principal Scientist, Novartis
Opportunity to network and diverse topics covering all stages of drug development.
Head of Clinical Development Pulmonology & Rheumatology, Boehringer Ingelheim
I attended last year's meeting, and without hesitation, it was the most valuable conference I attended. Bringing together leading scientists, clinicians, and CROs working across fibrotic diseases created an exceptional environment for sharing ideas and learning from one another. The breadth of science and the quality of the discussions made it a truly worthwhile and impactful few days
Chief Technical Officer, Animate Biosciences
Opportunity to network and diverse topics covering all stages of drug development.
Head of Clinical Development Pulmonology & Rheumatology, Boehringer Ingelheim
The Antifibrotic Drug Development Summit provides a unique opportunity to translate new insights from tissue homeostasis directly into the antifibrotic target engine — closing the loop between human biology and therapeutic innovation. Meetings like this are invaluable precisely because fibrosis does not respect organ boundaries: the pathogenic programs driving aberrant cellular activation and dysfunctional repair processes share common mechanistic threads, and cross-disease dialogue accelerates the pace at which we can move from biological insight to clinical proof-of-concept.
I am particularly energized by the opportunity to discuss how emerging modalities can be brought to bear on targets that conventional treatments have struggled to address.
The collaborative spirit of this forum is exactly what the field needs to translate the omics revolution into therapies that genuinely halt or reverse fibrosis, delivering truly disease-modifying outcomes to patients.
Head of Tissue Homeostasis, AbbVie
Opportunity to network and diverse topics covering all stages of drug development.
Head of Clinical Development Pulmonology & Rheumatology, Boehringer Ingelheim